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Cis-2,6-disubstituted piperdine analogs, or lobeline analogs, 
having the general formula: 
R4 
)1. 
R1 
are used to treat diseases of the central nervous system, drug 
abuse and Withdrawal therefrom as Well as to treating eating 
disorders. 
18 Claims, No Drawings 
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CIS-2,6-DISUBSTITUTED PIPERIDINES FOR 
THE TREATMENT OF PSYCHOSTIMULANT 
ABUSE AND WITHDRAWAL, EATING 
DISORDERS, AND CENTRAL NERVOUS 
SYSTEM DISEASES AND PATHOLOGIES 
This application claims the bene?t of Provisional Appli 
cation No. 60/146,144, ?led on Jul. 30, 1999. 
FIELD OF THE INVENTION 
The present invention relates to lobeline analogs, speci? 
cally cis-2,6-disubstituted piperidines, and their method of 
use in the treatment of diseases and pathologies of the 
central nervous system (CNS), the treatment of drug abuse 
and WithdraWal therefrom as Well as to the treatment of 
eating disorders such as obesity. 
BACKGROUND OF THE INVENTION 
Alpha-Lobeline (lobeline), a lipophilic nonpyridino, alka 
loidal constituent of Indian tobacco, is a major alkaloid in a 
family of structurally-related compounds found in Lobelia 
in?ata. Lobeline has been reported to have many nicotine 
like effects, including tachycardia and hypertension (Olin et 
al., 1995), hyperalgesia (Hamann et al., 1994) and improve 
ment of learning and memory (Decker et al., 1993). Lobeline 
has high af?nity for nicotinic receptors (Lippiello et al., 
1986; Broussolle et al., 1989). HoWever, no obvious struc 
tural resemblance of lobeline to nicotine is apparent and 
structure function relationships betWeen S(-)-nicotine and 
lobeline do not suggest a common pharmacophore (BarloW 
et al., 1989). Also, differential effects of lobeline and nico 
tine suggest that these drugs may not be active through a 
common CNS mechanism, even though lobeline has been 
considered a mixed nicotinic agonist/antagonist. 
Lobeline evokes dopamine (DA) release from rat striatal 
slices. HoWever, lobeline evoked DA release is neither 
dependent upon extracellular calcium nor is it sensitive to 
mecamylamine, a noncompetitive nicotinic receptor antago 
nist. Thus, lobeline evoked DA release occurs via a different 
mechanism than does nicotine to evoke DA release (Teng et 
al., 1997, 1998; Clarke et al., 1996). In this respect, lobeline 
also inhibits DA uptake into rat striatal synaptic vesicles via 
an interaction With the dihydrotetrabenaZine (DTBZ) site on 
vesicular monoamine transporter-2 (VMAT2), thus increas 
ing the cytosolic DA available for reverse transport by the 
plasma membrane transporter (DAT) (Teng et al., 1997, 
1998). Thus, lobeline interacts With nicotinic receptors and 
blocks nicotine-evoked DA release, but also interacts With 
DA transporter proteins to modify the concentration of DA 
in the cytosolic and vesicular storage pools, thereby altering 
subsequent dopaminergic neurotransmission. 
SUMMARY OF THE INVENTION 
The present invention is directed to a method of treating 
an individual Who suffers from a disease or pathology of the 
central nervous system (CNS) or for treating an individual 
for drug dependence or WithdraWal for drug dependence. 
The method comprises of administering to the individual an 
effective amount of a cis-2,6-substituted piperidino 
compound, i.e., a lobeline analog, including pharmaceuti 
cally acceptable salts of such compounds thereof. As used 
herein, an “effective amount” refers to an amount of a drug 
effective to reduce an individual’s desire for a drug of abuse 
or for food, or for alleviating at least one of the symptoms 
of the disease or pathological symptom of a CNS pathology. 
The compound can be administered alone, combined With 
an excipient, co-administered With a second drug having a 
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similar or synergistic effect. The compound is administered 
subcutaneously, intramuscularly, intravenously, 
transdermally, orally, intranasally, intrapulmonary or rec 
tally. The use of cis-2,6-disubstituted piperidines and deriva 
tives thereof in treating diseases or pathologies of the CNS 
is implicated. In particular, the treatment of dependencies of 
such drugs as cocaine, amphetamine, caffeine, nicotine, 
phencyclidine, opiates, barbiturates, benZodiaZepines, 
canabinoids, hallucinogens, and alcohol is implicated. Also, 
the treatment of eating disorders such as obesity is impli 
cated. 
In a preferred aspect of the invention, the method of 
treatment reduces an individual’s desire for the drug of 
abuse or for food by at least one day, but it is also preferred 
that the treatment method further comprise administering 
behavior modi?cation counseling to the individual. 
Although the compound of the present invention is contem 
plated primarily for the treatment of drug abuse and With 
draWal and for eating disorders, other uses are also sug 
gested by the studies discussed herein. Thus, cognitive 
disorders, brain trauma, memory loss, psychosis, sleep 
disorders, obsessive compulsive disorders, panic disorders, 
myasthenia gravis, Parkinson’s disease, AlZheimer’s 
disease, schiZophrenia, Tourette’s syndrome, Huntington’s 
disease, attention de?cit disorder, hyperkinetic syndrome, 
chronic nervous exhaustion, narcolepsy, motion sickness 
and depression, and related conditions are considered to be 
susceptible to treatment With a compound of the present 
invention. 
As shoWn by the results of the studies described herein, 
lobeline analogs are found to be effective in inhibiting 
uptake of extracellular DA by cells of the CNS. Some of 
these analogs are a also nicotinic receptor antagonists. Either 
or both mechanisms can thereby Work to alter the distribu 
tion of the intracellular DA pools and as a result alter 
extracellular DA concentration. 
As used herein the term “lobeline” refers to a compound 
having the general chemical formula 2-[6-([3 
hydroxyphenethyl)-1-methyl-2-piperidyl]-acetophenone. 
The term “lobeline analogs” and equivalents thereof as used 
herein, refers to chemical derivatives of lobeline obtained by 
oxidation or reduction of lobeline, others obtained by esteri 
?cation of lobeline and redox derivatives, as Well as various 
substitutions at the N-position of the piperidinyl moiety. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The 2,6-disubstituted piperidine lobeline analogs of the 
present invention include those contemplated by the folloW 
ing formula (I), Without regard to chirality: 
Wherein: 
n is Zero or an integer in the range from 1 to 3; 
X1 - - - Y1 and X2 - - - Y2 are the same or are 
independently different from one another and represent 
a saturated carbon-carbon bond, a cis-carbon-carbon 
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double bond, a trans-carbon-carbon double bond, a 
carbon-carbon triple bond; a saturated sulfur-carbon 
bond, a saturated selenium-carbon bond, an oXygen 
carbon bond, a saturated nitrogen-carbon bond, a 
N-alkyl substituted saturated nitrogen-carbon bond 
Where said alkyl is a loWer straight chain or branched 
alkyl, a nitrogen-carbon double bond, or a nitrogen 
nitrogen double bond; 
R1 and R4 are the same or are independently different 
from one another and represent hydrogen or a loWer 
straight chain or branched alkyl or R1 and R4 together 
R2 and R3 are the same or are independently different 
from one another and represent a saturated or unsatur 
ated hydrocarbon ring; a nitrogen containing heterocy 
clic moiety; an oxygen containing heterocyclic moiety; 
a sulfur containing heterocyclic moiety; a selenium 
containing heterocyclic moiety; a mixed heterocyclic 
moiety containing at least tWo atoms selected from the 
group consisting of nitrogen, oXygen and sulfur; and an 
ortho, meta or para-substituted benZene; 
With the proviso that When n=0, R2 and R3 are unsubsti 
tuted phenyl groups, and X1 - - - Y1 and X2 - - - Y2 are 
saturated carbon-carbon bonds, Y1 cannot be CH2, 
CHOH or C=O, and Y2 cannot be CH2, CHOH, or 
C=O. 
It is preferred that When R3 and/or R4 is a saturated 
hydrocarbon ring, the ring includes, but is not limited to, 
cyclobutane, cyclopentane, cycloheXane, cycloheptane or 
cyclooctane, including all possible substitution patterns, 
geometric and stereoisomers, racemic, diastereomeric and 
enantiomeric forms thereof. 
It is further preferred that When R3 and/or R4 is an 
unsaturated hydrocarbon ring, the ring includes, but is not 
limited to, benZene, cyclopentene, cycloheXene, 
cycloheptene, cyclooctene or cyclopentadiene, including all 
possible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric and enantiomeric forms thereof. 
It is further preferred that When R3 and/or R4 is a nitrogen 
containing heterocyclic moiety, the moiety includes, but is 
not limited to, aZetine, piperdine, piperaZine, pyraZine, 
pyraZole, pyraZolidine, imidaZole imidaZoline, pyrimidine, 
heXa-hydropyrimidine, pyrrole, pyrrolidine, triaZine, 1,2,3 
triaZole, 1,2,4-triaZole, pyridine or pyridaZine, including all 
possible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric and enantiomeric forms thereof. 
It is further preferred that R3 and/or R4 is an oXygen 
containing heterocyclic moiety, the moiety includes, but is 
not limited to, furan, tetrahydrofuran, 2,5-dihydrofuran, 
pyran, tetrahydropyran, 1,4-dioXane, 1,3-dioXane or 1,4 
oXathinin, including all possible substitution patterns, geo 
metric and stereoisomers, racemic, diastereomeric and, 
enantiomeric forms thereof. 
It is further preferred that When R3 and/or R4 is a sulfur 
containing heterocyclic moiety, the moiety includes, but is 
not limited to, thietane, thiophene, thiophane, 2,5 
dihydrothiophene, 1,3-dithiolylium, 1,3-dithiolane, 1,2 
dithiolylium, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3 
dithane, 1,4-dithiane, or thiopyranylium, including all 
possible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric and enantiomeric forms thereof. 
It is further preferred that When R3 and/or R4 is a selenium 
containing heterocyclic moiety, the moiety includes, but is 
not limited to, selenophene, including all possible substitu 
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tion patterns, geometric and stereoisomers, racemic, diaste 
reomeric and enantiomeric forms thereof. 
It is further preferred that When R3 and/or R4 is a miXed 
heterocyclic moiety, the moiety includes, but is not limited 
to, thiaZolidine, thiaZole and oXaZin, including all possible 
substitution patterns, geometric and stereoisomers, racemic, 
diastereomeric and enantiomeric forms thereof. 
The substituted benZene includes at least one substituent, 
Where the substituent is selected from , but is not limited to, 
the group consisting of methyl, ethyl, propyl, isopropyl, 
butyl, sec-butyl, isobutyl, amino, N-methylamino, N,N 
dimethylamino, carboXylate, methylcarboXylate, 
ethylcarboXylate, propylcarboXylate, isopropylcarboXylate, 
carboXaldehyde, acetoXy, propionyloXy, isopropionyloXy, 
cyano, aminomethyl, N-methylaminomethyl, N,N 
dimethylaminomethyl, carboXamide, 
N-methylcarboXamide, N,N-dimethylcarboXamide, acetyl, 
propionyl, formyl, benZoyl, sulfate, methylsulfate, hydroXyl, 
methoXy, ethoXy, propoXy, isopropoXy, thiol, methylthio, 
ethylthio, propiothiol, ?uoro, chloro, bromo, iodo, 
tri?uoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, 
ureido, aZido, isocyanate, thioisocyanate, hydroXylamino 
and nitroso. 
It is preferred that When either X1 - - - Y1 or X2 - - - Y2 
is a saturated carbon-carbon bond, Y1 or Y2 represents CH2, 
CH—OH, CHO-alkyl Where said alkyl is a loWer straight 
chain or branched alkyl, CH—OSO2—C6H5, CH—OSO2 
p-C6H4CH3, CH—SH, C6H5—SH, CH—S-alkyl Where said 
alkyl is a loWer straight chain or branched alkyl, CH—NO2, 
CH—CF3, CH—NHOH, CH—OCHO, CH—F, CH—Cl, 
CH—Br, CH—I, CH—NH2, CH—NH-alkyl Where said 
alkyl is a loWer straight chain or branched alkyl, CH—N 
(alkyl)2 Where said alkyl is a loWer straight chain or 
branched alkyl, CH—OCONH2, CH—OCONH-alkyl 
Where said alkyl is a loWer straight chain or branched alkyl, 
CH—OCON(alkyl)2 Where said alkyl is a loWer straight 
chain or branched alkyl, CH—N3, C=O or C=S; CH—O 
aryl such as a phenyl, ortho-, meta-, or para-substituted 
phenyl Where the substituent is as described above; or a 
hydrocarbon or hetercyclic ring such as pyridyl, furanyl, 
naphthyl, thiaZole, selenothenyl, oXaZolyl, 1,2,3-triaZole, 
1,2,4-triaZole, imidaZoline, pyrimidine, pyridaZine or 
triaZine, including all possible substitution patterns, diaste 
reomeric and enantiomeric forms thereof. 
The loWer straight or branched alkyl can be an alkyl group 
containing one to seven carbon atoms. The preferred alkyl 
groups are methyl and ethyl. 
The above 2,6-substituted piperidino analogs are pre 
ferred in their cis-geometrical isomeric forms, or in their 
trans geometric forms, including all possible geometric, 
racemic, diasteriomeric, and enantiomeric forms thereof. 
The above cis-2,6-disubstituted piperidines as Well as 
analogs thereof can be administered in their free base form 
or as a soluble salt. Whenever it is desired to employ a salt 
of a cis-2,6-substituted piperidine or its analog, it is pre 
ferred that a soluble salt be employed. Some preferred salts 
include hydrochloride, hydrobromide, nitrate, sulfate, 
phosphate, tartrate, galactarate, fumarate, citrate, maleate, 
glycolate, malate, ascorbate, lactate, aspartate, glutamate, 
methanesulfonate, p-toluenesulfonate, benZenesulfonate, 
salicylate, proprionate, and succinate salts. The above salt 
forms may be in some cases hydrates or solvates With 
alcohols and other solvents. 
Apharmaceutical composition containing a compound of 
the invention is also contemplated, Which may include a 
conventional additive, such as a stabiliZer, buffer, salt, 
preservative, ?ller, ?avor enhancer and the like, as knoWn to 
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those skilled in the art. Representative buffers include 
phosphates, carbonates, citrates and the like. Exemplary 
preservatives include EDTA, EGTA, BHA, BHT and the 
like. Acornposition of the invention may be administered by 
inhalation, i.e., intranasally as an aerosol or nasal forrnula 
tion; topically, i.e., in the form of an ointrnent, cream or 
lotion; orally, i.e., in solid or liquid form (tablet, gel cap, 
tirne release capsule, poWder, solution, or suspension in 
aqueous or non aqueous liquid; intravenously as an infusion 
or injection, i.e., as a solution, suspension or ernulsion in a 
pharrnaceutically acceptable carrier; transderrnally, e.g., via 
a transderrnal patch; rectally as a suppository and the like. 
Generally, the pharrnacologically effective dose of a 
present compound is in the amount ranging from about 
1><10_5 to about 1 rng/kg body Weight/day. The amount to be 
administered depends to some extent on the lipophilicity of 
the speci?c compound selected, since it is expected that this 
property of the compound Will cause it to partition into fat 
deposits of the subject. The precise amount to be adminis 
tered can be determined by the skilled practitioner in vieW 
of desired dosages, side effects and medical history of the 
patient and the like. 
The cis-2,6-disubstituted piperidino analogs of the present 
invention exhibit selectivity for either neuronal nicotinic 
acetylcholine receptors and/or the dopamine transporter 
protein (DAT). The derivatives that are active toWards the 
nicotinic receptor generally do not interact With the DAT, 
and those that interact With the DAT shoW only modest 
nicotinic receptor activity. 
TABLE 1 
(H) 
s R 
Y%__ N /Y1 
2 N 1X1 
CH3 
Ki (MM) Ki (MM) 
[3H]—Nicotine [3H]—Doparnine 
Binding Uptake 
Compound Assay Assay 
1. x1 = x2 = cH2 0.0043 45 
Y2 = (S)—CHOH 
2. x1 = x2 = Y1 = Y2 = cH2 14.3 3.0 
3. x1 = x2 = cH2 0.0041 39 
Y1 = Y2 = 0:0 
5. x1, Y1 = x2, Y2 = trans CHICH >100 0.8 
6. x1 = cH2 0.13 3.0 
X2, Y2 = trans CHICH 
7. x1 = x2 = cH2 0.93 54 
Y2 = (R)—CHOH 
s. x1 = x2 = Y2 = cH2 0.16 8.9 
Y1 = (RS)—CHOH 
9. x1 = cH2 4.2 1.3 
Y1 = (S)—CHOH 
X2, Y2 = trans CHICH 
The nine cis-2,6-disubstituted piperidino derivatives 
listed in Table 1 have the chemical structure of formula (II). 
They Were assayed for nicotinic receptor interaction and 
inhibition of DAT activity. The cis-2,6-disubstituted piperi 
dino analogs of the present invention exhibit selectivity for 
either neuronal nicotinic acetylcholine receptors and/or the 
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dopamine transporter protein (DAT). The derivatives that 
are active toWards the nicotinic receptor generally do not 
interact With the DAT, and those that interact With the DAT 
shoW only modest nicotinic receptor activity. 
The nine compounds in Table 1 Were evaluated in the high 
af?nity [3H]nicotine binding assay and afforded inhibition 
constants values) ranging from 0.0043 pM to >100 pM. 
Five of these compounds Were in the range of 4—160 nM. 
Three of these compounds Were in the range of 0.93—14 FM. 
One compound was >100 RM. The cis-2,6-disubstituted 
piperidino derivatives listed in Table 1 Were also assayed for 
inhibition of DAT activity, i.e., inhibition of [3H]DA uptake 
into the doparninergic presynaptic terrninal. Nine corn 
pounds Were evaluated and afforded inhibition constants values) ranging from 0.08 pM to 54 pM. 
Removal of both functionalities of the lobeline rnolecule 
resulted in loss of affinity for the nicotinic receptor and a 
100-fold more potent inhibition of the dopamine transporter 
compared with lobeline. Removal of either the hydroxyl 
group or the keto group of lobeline resulted in a 50-fold loss 
of af?nity for the nicotinic receptor. Interestingly, the 
ketoalkene analog inhibited DAT 10-fold more potently than 
lobeline, Whereas lobelanidine inhibited DAT equipotently 
compared to lobeline. Conversion of the hydroxy group of 
lobeline to a bulky tosyloxy group reduced the af?nity of the 
nicotinic receptor by only 3-fold, but did not alter the 
interaction With the DA transporter. The hydroxyalkene had 
a similar potency With the rneso-transdiene (the most potent 
compound) in the DA uptake assay, but had 1000-fold loWer 
af?nity for the nicotinic receptor. Also, the completely 
defunctionaliZed lobeline molecule and the hydroxyalkane 
analog Were both less potent than the rneso-transdiene in 
inhibiting DA uptake into striatal synaptosornes. This data 
indicates that appropriate structural rnodi?cation of the 
lobeline rnolecule affords compounds in Which the interac 
tion With DAT is enhanced. Furthermore, in one compound, 
i.e., the rneso-transdiene, the nicotinic receptor interaction 
has been eliminated and the compound is thus selective for 
inhibition of DAT. 
The invention Will noW be discussed by certain examples 
that illustrate but do not limit the invention. 
EXAMPLE 1 
Cis-2,6-di-trans-Styrylpiperidine 
1.00 g (2.95 rnrnol) of lobelanidine Was dissolved in 15 ml 
of 85% H3PO4 and alloWed to stir overnight at 60° C. The 
reaction mixture Was taken up in H20 and made basic With 
solid KZCO3 (pH~8). The pH Was adjusted by the addition 
of solid NaOH (pH~10). The aqueous solution Was extracted 
three times With 15 ml of EtOAc. The organic layers were? 
combined and dried over anhydrous MgSO4. The salts were 
removed via ?ltration and solvent removed by rotary evapo 
ration affording 0.70 g of crude product. This compound Was 
recrystallized from MeOH affording 0.60 g of pure cis-2,6 
di-trans-styrylpiperidine. Percent yield =78.6% 
Mp=139—141° C. 1H NMR (300 MHZ, CDCl3) d: 1.40—1.80 
(in, 6H), 2.23 (s, 3H), 2.50—2.64 (t, 2H), 6.04—6.20 (dd, 2H), 
6.39—6.50 (d, 2H) and 7.10—7.38 (in, 10H); 13C NMR 
(CDCl3) d: 23.75, 33.56, 42.32, 68.36, 126.26, 127.38, 
128.61, 130.52,133.89 and 137.13 pprn. 
EXAMPLE 2 
Cis-2S,6R, 8S-2-[(6-([3para 
Toluenesulfonyloxvphenethyl)-1 -rnethyl-2 
piperidyl]-acetophenone 
1.00 g (2.58 rnrnol) of lobeline hernisulfate Was dissolved 
in 25 ml. of pyridine and Was added dropWise to a solution 
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(cooled to 0° C.) containing 0.60 g (3.14 mmol) of 
p-toluenesulfonyl chloride dissolved in 15 ml of pyridine. 
After addition, the reaction Was alloWed to stir for 2 hours 
and then poured into 50 ml of ice-cold Water and the mixture 
Was stirred for an additional tWo hours. The aqueous solu 
tion Was extracted three times With 25 ml of EtOAc. The 
organic layers Were combined and dried over anhydrous 
Na2SO4. The salts Were removed by ?ltration and the 
solvent Was removed by rotary evaporation affording 450 
mg of a pink-colored compound. The product Was recrys 
talliZed from acetone yielding 300 mg of the product. 
Percent yield=21.6% mp=169.1—171.0° C. 1H NMR (300 
MHZ, CDCl3) 6: 1.30—1.98 (m, 6H), 2.20 (s, 3H), 2.63—2.74 
(d, 3H), 2.95—3.20 (m, 2H), 3.61—3.78 (d, 1H), 3.83—4.12 
(m, 2H), 450—4.72 (m, 1H), 4.80—4.90 (d, 1H), 6.90—7.00 (d, 
2H), 7.10—7.50 (m, 8H , 7.50—7.60 (d, 2H), 7.80—7.90 (d, 
2H) and 9.85 (s, 1H); 3C NMR (CDCl3) 6: 21.16, 22.25, 
23.32, 23.55, 27.35, 38.29, 40.18, 40.07, 60.79, 63.69, 
71.05, 125.56, 125.76, 127.39, 128.28, 128.44, 128.69, 
128.77, 133.67, 133.96,135.87, 140.03, 141.98,144.47 and 
195.21 ppm. 
EXAMPLE 3 
Cis-2S,6R-N-Methyl-6-phenacyl-2-trans 
styrylpiperidine 
1.00 g (2.58 mmol) of lobeline hemisulfate Was dissolved 
in 15 ml of 85% H3PO4 and the solution Was alloWed to stir 
for 24 hrs at 50° C. Phosphoric acid Was, then neutraliZed 
With K2CO3, and a little ice cold H2O Was added to dissolve 
the salts. The aqueous solution Was extracted With ethyl 
acetate (20 ml><3). The organic layers Were combined and 
dried With anhydrous MgSO4. The salts Were removed by 
?ltration and the solvent Was removed via rotary 
evaporation, affording 0.80 g of a gummy solid, Which 
contained mainly the trans isomer. Percent yield=84.6%. 1H 
NMR (300 MHZ, CDCl3) 1.15—1.60 (m, 6H), 2.02 (s, 3H), 
2.47(m, 3H), 3.16—3.34 (dd, 1H), 5.80—6.00 (dd, 1H), 
6.18—6.28 (d, 1H), and 6.90—7.38 8H) and 7.64—7.80 (d, 
2H); 13C NMR (CDCl3) 23.52, 32.56, 33.17, 40.52, 44.02, 
5.9.62, 68.08, 126.00, 127.15, 127.92, 128.36, 128.44, 
130.29, 132.91, 133.91, 136.95, 136.99 and 198.83 ppm. 
EXAMPLE 4 
Cis-10R,2S,6R- and Cis-10S,2S,6R-N-Methyl-6-[1 
-(2-hydroxy-2-phenyl)-ethyl]-2-trans-styryliperidine 
In a 250 ml round bottom ?ask Was added 0.80 g of 
cis-2S,6R-N-methyl-6-phenacyl-2-trans-styrylpiperidine, 
and 50 ml of ethanol. Sodium borohydride Was added until 
all of the starting material Was consumed (determined by 
TLC). The solution Was cooled to 00 C. and acetone Was 
added in small portions to quench the reaction. The solvents 
Were evaporated to dryness and Water Was added precipi 
tating 0.75 g of an off-White crystalline solid (1:1) mixture 
of diastereomers, Which Was puri?ed on silica eluting With 
75:25 (CHCl3/EtOH). The yield of the product (a mixture of 
diastereomers) Was 93.4%. 1H NMR (300 MHZ, CDCl3) 6: 
1.17—2.06 (m, 12H), 2.12 (s, 3H), 2.35 (s, 3H), 2.50—6.20 
(m, 4H), 2.70—3.20 (m, 4H), 4.78—4.80 (dd, 1H), 5.04—5.14 
(dd, 1H), 5.96—6.20 m, 2H), 6.32—6.42 (dd, 2H) and 
7.04—7.34 (m, 20H); 1 C NMR (CDCl3) 6: 23.69, 24.15, 
26.74, 29.68, 33.26, 39.94, 41.10, 41.41, 62.93, 63.00, 
65.62, 68.32, 71.76, 15 73.90,125.46,126.15, 126.19, 
126.83, 127.01,127.37, 128.16, 128.23, 128.50, 130.58, 
132.61, 133.85, 136.83, 136.95, 145.32 and 145.45 ppm. 
EXAMPLE 5 
Cis-2S 6R-N-Methyl-6-[1-(2-hydroxy-2-phenyl) 
ethyl]2-phenylethlypiperidine 
0.50 g (1.55 mmol) of cis-2S,6R-N-methyl-6-phenacyl 
2-trans-styrylpiperidine Was dissolved in 50 ml of ethanol 
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and placed into a Parr hydrogenation apparatus With 0.10 g 
of 10% Pd-on-Carbon. After removal of air, hydrogen gas 
Was introduced until a pressure of 40 psig Was reached. The 
reaction Was alloWed to proceed for 48 hrs. The Pd catalyst 
Was removed through ?ltration With Celite, and ethanol Was 
removed by rotary evaporation to afford 0.30 g of a yelloW 
oil. The compound Was puri?ed by silica gel chromatogra 
phy eluting With EtOAc to afford 0.25 g of the product. The 
yield Was 50.0%. 1H NMR (300 MHZ, CDCl3) 6: 0.70—0.90 
(m, 6H), 1.18 (s, 3H), 1.40—1.90 (m, 6H), 2.44—2.56 (m, 
2H), 4.564.60 (dd, 1H) and 7.04—7.30 (m, 10H); 13C NMR 
(CDCl3) 6: 25.77, 29.24, 29.38, 29.42, 29.46, 29.68, 31.44, 
35.93, 39.07, 74.64, 125.50,125.85,127.42, 128.17,128.35, 
128.37, 142.85 and 144.91 ppm. 
EXAMPLE 6 
High Affinity [3H]Nicotine Binding Assay 
The ability to displace S(-)[3H]NIC binding from rat 
striatal membranes to assess interaction With the (x4 [32 
subtype Was determined. The [3H]NIC binding assay Was 
performed according to previously published methods 
(Romano et al., 1980; Marks et al., 1986; Crooks et al., 
1995). Striata from tWo rats Were dissected, pooled and 
homogeniZed With a Tekmar polytron in 10 vol of ice-cold 
modi?ed Krebs-HEPES buffer (in mM; 20 HEPES, 118 
NaCl, 4.8 KCl, 2.5 CaCl2, 1.2 MgSO4, adjusted to pH to 
7.5). The homogenate Was incubated at 37° C. for 5 minutes 
to promote hydrolysis of endogenous acetylcholine, and 
centrifuged at 15,000 g for 20 minutes and the pellet Was 
resuspended in 10 vol of ice-cold distilled Water and incu 
bated at 37° C. for 5 minutes, folloWed by centrifugation at 
15,000 g for 20 min. The pellet containing the striatal 
membranes Was resuspended in 10 vol of fresh ice-cold 10% 
Krebs-HEPES buffer and incubated at 37° C. for 10 min 
after Which it Was centrifuged at 15,000 g for 20 minutes. 
The latter sequence of resuspension, incubation and cen 
trifugation Was repeated. The pellet Was froZen under fresh 
Krebs-HEPES buffer and stored at —40° C. until assay. Upon 
assay, the pellet Was resuspended in Krebs-HEPES buffer, 
incubated at 37° C. for 5 minutes and centrifuged at 15,000 
g for 20 min. The ?nal pellet Was resuspended in 3.6 ml 
ice-cold Water Which provides for approximately 200 pg 
protein/100 pl aliquot. Competition assays Were performed 
in duplicate in a ?nal volume of 200 pl Krebs-HEPES buffer 
containing 250 mM Tris buffer (pH 7.5 at 4° C.). Reactions 
Were initiated by addition of 100 pl of membrane suspension 
to 3 nM [3H]NIC (50 pl) and 1 of at least 9 concentrations 
of analog (50 pl). After 90 minutes incubation at 4° C., 
reactions Were terminated by dilution of the samples With 3 
ml of ice-cold buffer folloWed immediately by ?ltration 
through a Whatman GF/B glass ?ber ?lters (presoaked in 
0.5% polyethyleneimine (PEI) using a Brandel Cell Har 
vester. Filters Were rinsed 3>< With 3 ml of ice-cold buffer, 
transferred to scintillation vials and 5 ml scintillation cock 
tail added. Nonspeci?c binding Was de?ned as binding in the 
presence of 10 pM NIC. For competition curves, the IC5O 
values Were corrected for ligand concentration (Cheng et al., 
1973). 
EXAMPLE 7 
[3H]Dopamine ([3H]DA) Uptake Assay, Striatal 
Synaptosomal Preparation 
[3H]DA uptake Was performed according to a modi?ca 
tion of the previously reported methods (DWoskin et al., 
1999). Striata Were homogeniZed in 20 ml of ice-cold 
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sucrose solution (0.32 M sucrose and 5 mM sodium 
bicarbonate, pH 7.4) With 12 passes of a te?on-pestle 
homogeniZer (clearance approximately .003 in). The homo 
genate Was centrifuged at 2,000 g, 40 C. for 10 min. The 
supernatant Was centrifuged at 12,000 g, 40 C, for 20 
minutes. The resulting pellet Was resuspended in 1.5 ml 
ice-cold assay buffer (in mM; 125 NaCl, 5 KCl, 1.5 
KH2PO4, 1.5 MgSO4, 1.25 CaCl2, 10 glucose, 0.1 
L-ascorbate, 25 HEPES, 0.1 EDTA and 0.1 pargylin pH 7.4). 
The ?nal protein concentration Was 400 pig/ml. Assays Were 
performed in duplicate in a total vol of 500 pl. Aliquots (50 
pl synaptosomal suspension containing 20 pg of protein) 
Were added to assay tubes containing 350 pl buffer and 50 
pl of 1 of 9 concentrations (?nal concentration, 1 nM—1 mM) 
of analog or vehicle. Synaptosomes Were preincubated at 
34° C. for 10 min before the addition of 50 pl of [3H]DA 
(30.1 Ci/mmole, ?nal concentration 10 nM) and accumula 
tion proceeded for 10 min at 34° C. High af?nity uptake Was 
de?ned as the difference betWeen accumulation in the 
absence and presence of 10 pM GBR 12935. Preliminary 
studies demonstrated that at 10 minutes [3H]DA uptake is 
Within the linear range of the time-response curve When 
experiments are performed at 34° C. Accumulation Was 
terminated by addition of 3 ml ice-cold assay buffer con 
taining 1 mM pyrocatechol and rapid ?ltration through a 
Whatman GF/B glass ?ber ?lter paper (presoaked With 
buffer containing 1 mM pyrocatecol) using a Brandel Cell 
Harvester. The ?lters Were Washed 3 times With 3 ml of 10 
ml ice-cold buffer containing 2 mM pyrocatechol, and then 
transferred to scintillation vials and radioactivity determined 
(Packard Model B1600TR scintillation counter, Meriden, 
Conn.). Protein concentration Was determined using bovine 
serum albumin as the standard (Bradford, 1976). Competi 
tion curves for analog inhibition of [3H]DA uptake Were 
generated. Nonlinear regression analysis Was used to ?t 
curves either in the absence or presence of 9 concentrations 
of analog. IC50 values Were corrected for concentration of 
[3H]DA (Cheng-Prusoff, 1973) to yield true inhibition con 
stants (Ki=IC50/[1+c/Km]), Where c is the concentration of 
free [3H]DA and Km is the concentration of analog at Which 
half maXimal [3H]DA uptake is achieved. These values Were converted to pKi before statistical analy is. 
In the eXamples listed in the Table, a series of cis-2,6 
disubstituted piperidines, structurally related to lobeline, 
Were synthesiZed and tested for activity in the high affinity 
nicotinic receptor binding assay and the dopamine uptake 
assay to assess the interaction of these piperidines With these 
speci?c proteins on the presynaptic terminal of dopaminer 
gic neurons in the CNS. Some of these compounds have 
greater selectivity for interaction With DAT than for inter 
action With nicotinic receptors, Whereas other compounds 
interact With both nicotinic receptors and DAT, more similar 
to lobeline. Other compounds Were more selective for the 
nicotinic receptor than for DAT. These combinations of 
pharmacological activity are considered to be bene?cical for 
the treatment of psychostimulant abuse and WithdraWal, 
eating disorders, and central nervous system diseases and 
pathologies. 
The foregoing is considered as illustrative only of the 
principles of the invention. Further, since numerous modi 
?cations and changes Will readily occur to those skilled in 
the art, it is not desired to limit the invention to the eXact 
construction and operation shoWn and described, and 
accordingly, all suitable modi?cations and equivalence 
thereof may be resorted to, falling Within the scope of the 
invention claimed. 
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What is claimed is: 
1. A cis-2,6-substituted piperidino compound or pharma 
ceutically effective salt thereof comprising formula (I): 
(I) 
R4 
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wherein: 
X1 - - - Y1 and X2 - - - Y2 are the same or are 
independently different from one another and represent 
a saturated carbon-carbon bond, X1 and X2 represent 
CH2 or CH=CH, and Y1 and Y2 represent CH2 or 
CH=CH, C=O or CHOH; 
R1 and R4 are the same or are independently different 
from one another and represent hydrogen or a loWer 
straight chain or branched alkyl; and 
R2 and R3 are the same or are independently different 
from one another and represent a saturated or unsatur 
ated hydrocarbon ring; 
With the proviso that When R2 and R3 are unsubstituted 
phenyl groups, Y1 and Y2 cannot be CHOH or C=O. 
2. The compound of claim 1, Wherein the saturated 
hydrocarbon ring includes cyclobutane, cyclopentane, 
cycloheXane, cycloheptane or cyclooctane. 
3. The compound of claim 1, Wherein the unsaturated 
hydrocarbon ring includes benZene, cyclopentene, 
cycloheXene, cycloheptene, cyclooctene or cyclopentadiene. 
4. The compound of claim 1, Wherein the pharmaceutical 
salts are hydrochloride, hydromide, sulfate, hydrosulfate, 
citrate, fumarate or tartrate salts of said compound. 
5. The compound of claim 1, Wherein said loWer straight 
chain or branched alkyl contains one to seven carbon atoms. 
6. The compound of claim 5, Wherein said alkyl is methyl 
or ethyl. 
7. The compound of claim 1, herein said compound is 
cis-2S,6R-N-methyl-6-[1-(2-hydroXy-2-phenyl)ethyl] 
-2-phenylethylpiperdine. 
8. A method of treating an individual for dependence on 
a drug of abuse, WithdraWal from a drug of abuse, for an 
eating disorder, or for a CNS disease or pathology compris 
ing administering to the individual an effective amount of a 
cis-2,6-substituted piperidino compound or pharmaceuti 
cally effective salt thereof comprising formula (I): 
(I) 
R4 
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Wherein said administering of the compound inhibits uptake 
of dopamine by cells of the central nervous system of the 
individual and Wherein: 
X1 - - - Y1 and X2- - - Y2 are the same or are indepen 
dently different from one another and represent a 
saturated carbon-carbon bond, X1 and X2 represent 
CH2 or CH=CH, and Y1 and Y2 represent CH2 or 
CH=CH, C=O or CHOH; 
R1 and R4 are the same or are independently different 
from one another and represent hydrogen or a loWer 
straight chain or branched alkyl; and 
R2 and R3 are the same or are independently different 
from one another and represent a saturated or unsatur 
ated hydrocarbon ring; 
With the proviso that When R2 and R3 are unsubstituted 
phenyl groups, Y1 and Y2 cannot be CHOH or C=O. 
9. The method of claim 8, Wherein the saturated hydro 
carbon ring includes cyclobutane, cyclopentane, 
cycloheXane, cycloheptane or cyclooctane. 
10. The method of claim 8, Wherein the unsaturated 
hydrocarbon ring includes benZene, cyclopentene, 
cycloheXene, cycloheptene, cyclooctene or cyclopentadiene. 
11. The method of claim 8, Wherein the pharmaceutical 
salts are hydrochloride, hydrobromide, sulfate, hydrosulfate, 
citrate, fumarate or tartrate salts of said compound. 
12. The method of claim 8, Wherein said loWer straight 
chain or branched alkyl contains one to seven carbon atoms. 
13. The method of claim 8, Wherein said alkyl is methyl 
or ethyl. 
14. The method of claim 8, Wherein said compound is 
cis-2S,6R-N-methyl-6-[-(1-2-hydroXy-2-phenyl)ethyl]-2 
phenylethylpiperdine. 
15. The method of claim 8, Wherein said compound is 
cis-2,6-di-trans-styrylpiperdine. 
16. The method of claim 8, Wherein said compound is 
cis-2S,6R-N-methyl-6-phenacyl-2-trans-styrylpiperdine. 
17. The method of claim 8, Wherein said compound is 
cis-10R,2S,6R-N-methyl-6-[-2(-hydroXy-2-phenyl)-ethyl] 
2-trans-styrylpiperdine. 
18. The method of claim 8, Wherein said compound is 
cis-10S,2S,6R-N-methyl-6-[1I-2(-hydroXy-2-phenyl) 
ethyl]-2-trans-styrylpiperdine. 
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